Literature DB >> 1436520

Markers of dopamine metabolism in Parkinson's disease. The Parkinson Study Group.

P A LeWitt1, M P Galloway, W Matson, P Milbury, M McDermott, D K Srivastava, D Oakes.   

Abstract

We used two analytic methods (a multichannel coulometric electrode array with high-performance liquid chromatography, and gas chromatography-mass spectrophotometry) to measure CSF dopamine (DA) and its metabolites in mildly affected, unmedicated subjects with Parkinson's disease (PD). The mean (+/- SD) concentration of homovanillic acid (HVA), the most abundant product of DA turnover, was 164.57 +/- 95.05 nM. As sequential aliquots of CSF were collected from the first to 23rd ml, CSF HVA concentration almost doubled. After HVA, 3-O-methyldopa (3-O-MD) was the next most abundant compound. The summed concentrations of 3-O-MD, 3,4-dihydroxyphenylacetic acid, 3-methoxytyramine, DA, DA-3-sulfate, homovanillol, and levodopa (LD) amounted to 12.6% of HVA. Concentrations of the DA metabolites did not correlate to a variety of indices of PD severity. The presence of LD and 3-O-MD may be indicators of DA synthesis and possibly could reflect compensatory processes among surviving dopaminergic neurons of the PD brain.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1436520     DOI: 10.1212/wnl.42.11.2111

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  20 in total

1.  Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease.

Authors:  S Engelborghs; B Marescau; P P De Deyn
Journal:  Neurochem Res       Date:  2003-08       Impact factor: 3.996

Review 2.  CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD.

Authors:  Alessandro Stefani; Livia Brusa; Enrica Olivola; Mariangela Pierantozzi; Alessandro Martorana
Journal:  J Neural Transm (Vienna)       Date:  2012-05-24       Impact factor: 3.575

3.  Metabolomic changes in autopsy-confirmed Alzheimer's disease.

Authors:  Rima Kaddurah-Daouk; Steve Rozen; Wayne Matson; Xianlin Han; Christine M Hulette; James R Burke; P Murali Doraiswamy; Kathleen A Welsh-Bohmer
Journal:  Alzheimers Dement       Date:  2010-11-13       Impact factor: 21.566

4.  Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease.

Authors:  A Moser; F Siebecker; P Vieregge; P Jaskowski; D Kömpf
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

5.  CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease.

Authors:  Peter LeWitt; Lonni Schultz; Peggy Auinger; Mei Lu
Journal:  Brain Res       Date:  2011-07-01       Impact factor: 3.252

6.  Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies.

Authors:  David S Goldstein; Courtney Holmes; Patricia Sullivan; Yunden Jinsmaa; Irwin J Kopin; Yehonatan Sharabi
Journal:  Parkinsonism Relat Disord       Date:  2016-07-20       Impact factor: 4.891

7.  Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies.

Authors:  David S Goldstein; Courtney Holmes; Yehonatan Sharabi
Journal:  Brain       Date:  2012-03-26       Impact factor: 13.501

8.  Decreased beta-phenylethylamine in CSF in Parkinson's disease.

Authors:  G Zhou; H Shoji; S Yamada; T Matsuishi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-12       Impact factor: 10.154

9.  Urate as a predictor of the rate of clinical decline in Parkinson disease.

Authors:  Alberto Ascherio; Peter A LeWitt; Kui Xu; Shirley Eberly; Arthur Watts; Wayne R Matson; Connie Marras; Karl Kieburtz; Alice Rudolph; Mikhail B Bogdanov; Steven R Schwid; Marsha Tennis; Caroline M Tanner; M Flint Beal; Anthony E Lang; David Oakes; Stanley Fahn; Ira Shoulson; Michael A Schwarzschild
Journal:  Arch Neurol       Date:  2009-12

10.  A rapid non invasive L-DOPA-¹³C breath test for optimally suppressing extracerebral AADC enzyme activity - toward individualizing carbidopa therapy in Parkinson’s disease.

Authors:  Anil Modak; Raymon Durso; Ephraim Josephs; David Rosen
Journal:  J Parkinsons Dis       Date:  2012       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.